Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009

Cell Death and Disease

Volumn 5, Issue 4, 2014, Pages

  Hsieh, I N ^a   Liou, J P ^b   Lee, H Y ^b   Lai, M J ^b   Li, Y H ^b   Yang, C R ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Epigenetic regulation; Histone deacetylase; Osteoclasts; Rheumatoid arthritis; Synovial fibroblasts

Indexed keywords

COLONY STIMULATING FACTOR 1; CYTOKINE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; MPT 0G 009; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; UNCLASSIFIED DRUG; VORINOSTAT; 3-(1-(4-METHOXYBENZENESULFONYL)-2,3-DIHYDRO-1H-INDOL-5-YL)-N-HYDROXYACRYLAMIDE; ANTIINFLAMMATORY AGENT; AUTACOID; HISTONE; HYDROXAMIC ACID; ISOPROTEIN; RECOMBINANT PROTEIN; SULFONAMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; BONE DESTRUCTION; CELL LYSATE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; INFLAMMATION; MACROPHAGE; MALE; MAXIMUM TOLERATED DOSE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; ACETYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; BIOSYNTHESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; FIBROBLAST; IC50; METABOLISM; ORAL DRUG ADMINISTRATION; OSTEOCLAST; PATHOLOGY; RABBIT; SYNOVIUM;

ACETYLATION; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; DISEASE MODELS, ANIMAL; FIBROBLASTS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HYDROXAMIC ACIDS; INFLAMMATION MEDIATORS; INHIBITORY CONCENTRATION 50; MACROPHAGE COLONY-STIMULATING FACTOR; MAXIMUM TOLERATED DOSE; MICE; OSTEOCLASTS; PROTEIN ISOFORMS; RABBITS; RANK LIGAND; RATS; RECOMBINANT PROTEINS; SULFONAMIDES; SYNOVIAL MEMBRANE;

EID: 84900992980     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.133     Document Type: Article

References (30)

1. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology 2012; 51(Suppl 5): v3-11.
2. Bartok B, Firestein GS. Fibroblast-like synoviocytes, key effector cells in rheumatoid arthritis. Immunol Rev 2010; 233: 233-255.
3. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet 2010; 376: 1094-1107.
4. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology 2011; 50: 124-131.
5. Smolen JS, Aletaha D, Koeller M, Weisman MH, Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007; 370: 1861-1874.
6. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004; 36: 372-378.
7. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012; 8: 656-664.
8. Choo QY, Ho PC, Lin HS. Histone deacetylase inhibitors: new hope for rheumatoid arthritis? Curr Pharm Des 2008; 14: 803-820.
9. Shakespear MR, Halili MA, Irvine KM, Fairlie DP, Sweet MJ. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
10. Hume DA, Fairlie DP. Therapeutic targets in inflammatory disease. Curr Med Chem 2005; 12: 2925-2929.
11. Joosten LA, Leoni F, Meghji S, Mascagni P. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol Med 2011; 17: 391-396.
12. Lee HY, Yang CR, Lai MJ, Huang HL, Hsieh YL, Liu YM et al. 1-Arylsulfonyl-5- (N-hydroxyacrylamide)indolines histone deacetylase inhibitors are potent cytokine release suppressors. Chem Bio Chem 2013; 14: 1248-1254.
13. Kameyama S, Yoshimura Y, Kameyama T, Kikuiri T, Matsuno M, Deyama Y et al. Short-term mechanical stress inhibits osteoclastogenesis via suppression of DC-STAMP in RAW264.7 cells. Int J Mol Med 2013; 31: 292-298.
14. Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling for terminal differentiation of osteoclasts. Dev Cell 2002; 3: 889-901.
15. Cantley MD, Bartold PM, Fairlie DP, Rainsford KD, Haynes DR. Histone deacetylase inhibitors as suppressors of bone destruction in inflammatory diseases. J Pharm Pharmacol 2012; 64: 763-774.
16. Huang HL, Lee HY, Tsai AC, Peng CY, Lai MJ, Wang JC et al. Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo. PLoS One 2012; 7: e43645.
17. Ku CS, Pham TX, Park Y, Kim B, Shih MS, Kang I et al. Edible blue-green algae reduce the production of pro-inflammatory cytokines by inhibiting NF-kB pathway in macrophages and splenocytes. Biochim Biophys Acta 2013; 1830: 2981-2988.
18. Grabiec AM, Korchynskyi O, Tak PP, Reedquist KA. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann Rheum Dis 2012; 71: 424-431.
19. Nasu Y, Nishida K, Miyazawa S, Komiyama T, Kadota Y, Abe N et al. Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage 2008; 16: 723-732.
20. Kawabata T, Nishida K, Takasugi K, Ogawa H, Sada K, Kadota Y et al. Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res Ther 2010; 12: R133.
21. Inoue K, Kobayashi M, Yano K, Miura M, Izumi A, Mataki C et al. Histone deacetylase inhibitor reduces monocyte adhesion to endothelium through the suppression of vascular cell adhesion molecule-1 expression. Arterioscler Thromb Vasc Biol 2006; 26: 2652-2659.
22. Pham L, Kaiser B, Romsa A, Schwarz T, Gopalakrishnan R, Jensen ED et al. HDAC3 and HDAC7 have opposite effects on osteoclast differentiation. J Biol Chem 2011; 286: 12056-12065.
23. De Zoeten EF, Wang L, Butler K, Beier UH, Akimova T, Sai H et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol 2011; 31: 2066-2078.
24. Cantley MD, Fairlie DP, Bartold PM, Rainsford KD, Le GT, Lucke AJ et al. Inhibitors of histone deacetylases in class I and class II suppress human osteoclasts in vitro. J Cell Physiol 2011; 226: 3233-3241.
25. Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA et al. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 2011; 6: e27746.
26. Hideshima T, Richardson PG, Anderson KC. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther 2011; 10: 2034-2042.
27. Simms-Waldrip T, Rodriguez-Gonzalez A, Lin T, Ikeda AK, Fu C, Sakamoto KM. The aggresome pathway as a target for therapy in hematologic malignancies. Mol Genet Metab 2008; 94: 283-286.
28. Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007; 26: 5468-5476.
29. Kim HN, Ha H, Lee JH, Jung K, Yang D, Woo KM et al. Trichostatin A inhibits osteoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Eur J Pharmacol 2009; 623: 22-29.
30. Venkatesh PR, Goh E, Zeng P, New LS, Xin L, Pasha MK et al. In vitro phase I cytochrome P450 metabolism, permeability and pharmacokinetics of SB639, a novel histone deacetylase inhibitor in preclinical species. Biol Pharm Bull 2007; 30: 1021-1024.